Table 2.
Internal standard–normalized matrix effect (IS‐nME), extraction recovery (IS‐nER), and process efficiency (IS‐nPE) in human plasma
| Compound | QC Levela | IS‐nME | IS‐nER | IS‐nPE |
|---|---|---|---|---|
| % (RSD) | % (RSD) | % (RSD) | ||
| Bictegravir/[13C,2H2,15N]‐Bictegravir | Low | 0 (6) | −6 (6) | −6 (7) |
| Middle | 3 (3) | −5 (3) | −2 (2) | |
| High | −5 (3) | −8 (4) | −12 (3) | |
| Cabotegravir/[13C, 2H5]‐Cabotegravir | Low | 5 (4) | −6 (6) | −1 (5) |
| Middle | −1 (3) | −6 (4) | −6 (3) | |
| High | −6 (3) | −7 (3) | −12 (3) | |
| Doravirine/[13C6]‐Doravirine | Low | 3 (5) | −11 (5) | −8 (3) |
| Middle | 4 (3) | −8 (3) | −5 (2) | |
| High | −4 (2) | −10 (3) | −13 (3) | |
| Rilpivirine/[13C6]‐Rilpivirine | Low | 12 (4) | −15 (10) | −5 (8) |
| Middle | 9 (5) | −4 (8) | 5 (3) | |
| High | −6 (3) | −11 (6) | −16 (4) |
Abbreviation: RSD, relative standard deviation.
a
Low concentrations are defined as 60 ng/mL (12 ng/mL for rilpivirine), middle concentrations are defined as 600 ng/mL (120 ng/mL for rilpivirine), and high concentrations are defined as 6000 ng/mL (1200 ng/mL for rilpivirine).